Document is current

Article History

Received: 12 September 2020

Accepted: 8 October 2020

First Online: 22 October 2020

Change Date: 11 November 2020

Change Type: Update

Change Details: In the original article, the third author name, ‘Niels Vande Casteele’ was published with ‘Niels Vande’ as the first name and ‘Casteele’ as the surname. The corrected first name and the surname of the author is Niels Vande Casteele - Niels (first name); Vande Casteele (surname).

Compliance with Ethical Standards

:

: Andres J Yarur: Consultant/Advisory boards Takeda and Prometheus Biosciences. Speaker fees for Takeda and Prometheus Biosciences. Parakkal Deepak: supported by a Junior Faculty Development Award from the American College of Gastroenterology. Consultant or advisory board member for Janssen, Pfizer and Prometheus, speaker’s bureau for AbbVie; research grant from Takeda. Niels Vande Casteele: research grants from R-Biopharm; grants and personal fees from Takeda and UCB; and personal fees from Alimentiv, Inc. (formerly Robarts Clinical Trials, Inc.), Celltrion and Prometheus. Robert Battat: no conflict of interests. Anjali Jain: Employee of and owns stock options for Prometheus Biosciences. Lauren Okada: Employee of Prometheus Biosciences. Mark Osterman: advisory board consultant for AbbVie, Elan, Genentech/Roche, Janssen, Lycera, Merck, Pfizer, Takeda, UCB; research grant support from UCB. Miguel Regueiro; Advisory Boards and Consultant for Abbvie, Janssen, UCB, Takeda, Pfizer, Miraca Labs, Amgen, Celgene, Seres, Allergan, Genentech, Gilead, Salix, Prometheus, Lilly, TARGET Pharma Solutions, ALFASIGMA, S.p.A.

: De-identified information was extracted from the clinical laboratory database. Clinical information that did not include the Health Insurance Portability and Accountability Act (HIPAA) identifiers were used for these analyses. The data were extracted from the Prometheus Biosciences database, National Institutes of Health criteria for exemption from human subject’s regulations (category 4) were met as all personal information was removed to protect privacy. This included all subject data being de-identified and the removal of all HIPAA identifiers prior to data extraction. The dataset was maintained with no possibility of identification of personal information. Data extraction was reviewed and approved by the Prometheus Biosciences privacy office for compliance. All authors had access to study data, and reviewed and approved the final manuscript.